Table 1.
Patients with detectable HBV DNA before liver transplantation had worse tumour characteristics.
| Groups |
|||
|---|---|---|---|
| Variables | HBV DNA neg (n = 75) | HBV DNA pos (n = 42) | p |
| Recurrence | .036 | ||
| 0 | 64 (85.3%) | 29 (69.0%) | |
| 1 | 11 (14.7%) | 13 (31.0%) | |
| BMI (Kg/m2) | 24.2(22.4, 26.1) | 24.7(22.5, 28.1) | .264 |
| AFP (ng/mL) | 6.7(3.0,29.4) | 82.3(8.3, 382.2) | <.001 |
| Tumour counts | 1 (1, 2) | 1 (1, 3) | .166 |
| Max tumour diameter (cm) | 2.5(1.5, 3.6) | 4.8 (2.5, 8.0) | .001 |
| Macrovascular invasion | 8 (10.7%) | 12 (28.6%) | .014 |
| Microvascular invasion | 46 (61.3%) | 34 (81.0%) | .029 |
| TNM stage | <.001 | ||
| I + II | 78(83.9%) | 12(50.0%) | |
| III + IV | 15(16.1%) | 12(50.0%) | |
| MELD score | 11.0 (8.0, 14.0) | 14.0 (9.0, 24.0) | .026 |
| Child score | 9.0 (8.0, 10.0) | 10.0 (8.0, 11.0) | .039 |
HBV DNA neg: HBV DNA undetectable; HBV DNA pos: HBV DNA detectable; BMI: Body mass index; AFP: alpha-fetoprotein; MELD: model for end stage liver disease.